Peptide Research Week in Review: 2-6 August 2026
TL;DR: This week: Lilly formalised retatrutide expanded access amid reported doctor pushback, a new MC4R mouse study, and a GLP-1 ad lawsuit nears injunction.
What Happened in Peptide Research This Week (2-6 Aug 2026)?
Two genuine developments landed on top of last week's lingering PCAC-vote fallout. First, Eli Lilly turned the single-patient retatrutide compassionate-use case it disclosed in June into a formal, cohort-level expanded access programme on 3 August, with STAT News reporting the move followed weeks of physicians separately requesting the same access for their own patients without a substantive reply.[1] Second, a peer-reviewed rodent study comparing retatrutide, tirzepatide and semaglutide in a genetically distinct obesity model reached wider coverage on 5 August, giving researchers a third reference point beyond the TRIUMPH human trial data.[2]
Alongside those two stories, two slower-moving regulatory tracks kept ticking without a resolution: the FDA's public comment window on excluding tirzepatide, semaglutide and liraglutide from the 503B Bulks List closed on 30 July with no ruling yet, and Novo Nordisk's advertising lawsuit against Eli Lilly is heading toward a 17 August preliminary-injunction motion.[3]
What Changed With Retatrutide's Expanded Access Programme This Week?
Lilly confirmed it is "actively reviewing requests from health care providers" under a new cohort protocol registered on ClinicalTrials.gov as NCT07629401, with published eligibility criteria: refractory obesity despite the highest approved dose of an existing therapy, at least two serious obesity-related complications, and no available clinical-trial alternative.[1]
Full breakdown: Eli Lilly Opens Retatrutide Expanded Access
The detail that adds context this week is the reported pressure behind the timing. STAT's 3 August report states that multiple physicians who separately sought compassionate-use access for their own patients after the original June case became public told the outlet they went weeks without a substantive response from Lilly, before the company published a defined pathway rather than continuing to field individual requests ad hoc.[1] That framing matters for how the programme should be read: it looks less like a proactive access initiative and more like a company formalising a process under public and clinical pressure.
None of this moves Lilly's regulatory clock. The company confirmed on 23 July that its Biologics License Application filing target remains Q1 2027, a decision tied to manufacturing and quality-control (CMC) data rather than trial results, and this week's expanded access news does not change that timeline in either direction.[4]
What Did the New MC4R Mouse Study Add to the Comparison Picture?
A study published in the International Journal of Obesity (Hitaka et al., PMID 41723268) dosed melanocortin-4-receptor-knockout (MC4R-KO) mice — a genetic model of severe, early-onset obesity anatomically distinct from the GLP-1, GIP and glucagon pathways that incretin-class peptides target — with semaglutide, tirzepatide or retatrutide for 21 days.[2] Body weight fell 19.7% on semaglutide, 31.6% on tirzepatide and 24.1% on retatrutide, with all three compounds also improving insulin sensitivity, cholesterol and liver-enzyme markers relative to untreated controls.[2]
This is rodent data in a single knockout strain over a short dosing window, not a ranking of relative human efficacy, and the study itself dates to February 2026 — it reached broader trade coverage only this week. We covered the full study design, limitations, and the one published human MC4R-mutation subgroup analysis (tirzepatide-only, from SURMOUNT-1) in our dedicated MC4R mouse study guide.
Where Do the FDA 503B Comment Period and the Novo-Lilly Lawsuit Stand?
Both tracks moved closer to their next milestone without a resolution landing this week. The FDA's public comment window on excluding tirzepatide, semaglutide and liraglutide from the Section 503B Bulks List — the compounding-pharmacy mechanism, separate from the 503A peptide vote covered in our earlier reporting — closed on 30 July with no final determination yet issued.[3] See our 503B comment period guide for the procedural detail.
Separately, Novo Nordisk's federal lawsuit against Eli Lilly, filed 21 July in the District of New Jersey over Zepbound and Mounjaro advertising claims, is heading toward a preliminary-injunction motion Novo has said it plans to file on 17 August 2026.[5] As of 6 August, no motion has been filed or heard; full background is in our Novo Nordisk v. Eli Lilly lawsuit guide.
How Do This Week's Stories Connect?
Access and evidence are moving on separate tracks. Lilly is expanding pre-approval access to retatrutide under clinical and public pressure at the same time as independent researchers keep publishing comparative preclinical data on the same molecule — the two are unrelated regulatory and scientific processes that happen to be converging in the news this week. Meanwhile, the two slower disputes (503B rulemaking, the Novo-Lilly lawsuit) are procedural and commercial, not scientific, and neither touches retatrutide's own Phase 3 evidence base.
For researchers, the practical read is the same one we've made in previous roundups: an access-pathway announcement is not new efficacy or safety data, and a mouse study in a knockout strain is not evidence about relative human outcomes. Keep the four threads separate when citing this week's news.
What Happens Next?
| Track | Next milestone | Expected timing |
|---|---|---|
| Retatrutide expanded access (NCT07629401) | Ongoing physician-led enrolment under published criteria | Open now |
| Retatrutide BLA (Lilly) | FDA filing submission | Q1 2027 |
| Novo Nordisk v. Eli Lilly lawsuit | Preliminary-injunction motion | 17 August 2026 |
| FDA 503B bulks list (tirzepatide, semaglutide, liraglutide) | Final determination | No date announced |
| PCAC batch 2 hearing | GHK-Cu, Melanotan II, LL-37, DiHexa, PEG-MGF review | Before end February 2027 |
What Should UK Researchers Take From This Week?
None of this week's developments change the regulatory status of research peptides in the UK. Lilly's expanded access programme is a US patient-treatment pathway administered under FDA oversight for its own branded investigational drug; the 503B process governs US compounding pharmacies; and the Novo-Lilly lawsuit is a commercial advertising dispute between two licensed manufacturers. None has any bearing on the Human Medicines Regulations 2012 or MHRA guidance governing research-use compounds sold in Great Britain and Northern Ireland. See our guide on whether research peptides are legal in the UK for the fuller picture.
Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA in our products. Not for human or veterinary consumption. See our Research Use Policy and MHRA Statement.
References
- STAT News. “Eli Lilly to offer retatrutide access given earlier to just one patient.” 3 August 2026. statnews.com
- Hitaka K, Sugawara T, Matsumoto M, et al. Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison. International Journal of Obesity 2026;50:928–937. nature.com, PMID 41723268.
- U.S. Food and Drug Administration. Proposal to exclude semaglutide, tirzepatide and liraglutide from the Section 503B Bulks List; public comment period closed 30 July 2026. fda.gov
- CNBC. “Eli Lilly will file for approval of retatrutide obesity drug in 2027.” 23 July 2026. cnbc.com
- Velox Peptides. “Novo Nordisk Sues Eli Lilly Over GLP-1 Ad Claims.” Summarising Novo Nordisk v. Eli Lilly, D.N.J., filed 21 July 2026. veloxpeps.com
Frequently Asked Questions
What's the biggest peptide research story this week (2-6 August 2026)?
Eli Lilly's 3 August confirmation that it has turned a single-patient compassionate-use case into a formal, cohort-level expanded access programme for retatrutide, published eligibility criteria and a ClinicalTrials.gov registration (NCT07629401). STAT News reported the move followed weeks of physicians separately seeking similar access for their own patients without a substantive response from Lilly.
What changed with Eli Lilly's retatrutide expanded access programme this week?
On 3 August 2026, Lilly moved from handling requests case by case to a defined cohort protocol (NCT07629401) with published eligibility criteria: refractory obesity, at least two serious obesity-related complications, and no available trial alternative. It does not change Lilly's Q1 2027 FDA filing target.
What did the new MC4R-deficient obesity mouse study add?
A peer-reviewed study (Hitaka et al., International Journal of Obesity, February 2026) dosed MC4R-knockout mice with semaglutide, tirzepatide or retatrutide for 21 days, reporting weight reductions of 19.7%, 31.6% and 24.1% respectively. It is rodent data addressing a genetically distinct obesity model, not a ranking of human efficacy.
When is the Novo Nordisk v. Eli Lilly GLP-1 ad lawsuit injunction hearing?
Novo Nordisk has said it plans to file a preliminary-injunction motion on 17 August 2026 in its federal lawsuit against Eli Lilly over Zepbound and Mounjaro advertising claims. As of 6 August, no motion has yet been filed or heard.
Does any of this week's news affect UK research-reagent supply?
No. Lilly's expanded access programme is a US patient-treatment pathway for its own branded investigational drug, the FDA's 503B process governs US compounding pharmacies, and the Novo-Lilly lawsuit is a commercial dispute between two licensed manufacturers. None changes the regulatory status of research peptides under the UK's Human Medicines Regulations 2012. Velox Peptides supplies every compound named as an HPLC-verified in vitro research reagent only.